OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
-- Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience -- |
[14-June-2021] |
PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Inc. (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of Product Engineering, effective June 14, 2021. Mr. Silverman, an engineering management veteran, brings to OncoSec extensive global industry experience spanning more than 20 years, in the development, manufacturing and scale up of Medical Devices including electroporation and gene delivery equipment for the delivery of DNA drugs in support of cancer and vaccine research. For more than five years, Mr. Silverman served as Vice President at Ichor Medical Systems, Inc., an industry leader focused on the development, manufacture and sale of electroporation devices for the intracellular delivery of nucleic acid-based drugs encoding therapeutic proteins. While at Ichor, he was responsible for establishing and leading the engineering, operations and quality teams for the company's electroporation equipment for the delivery of DNA drugs in support of cancer and vaccine research. Mr. Silverman was also responsible for engineering design execution and planning, supply chain, supplier audits, internal and external manufacturing and contract coordination. Prior to joining Ichor Medical Systems, Mr. Silverman was the Managing Director at Varioscale, Inc. Adding to his past experience, he held a variety of engineering and business manager roles, including his time at Abbott Laboratories and Guidant Corporation where he managed business alliance, program management, engineering/manufacturing process development and improvements. "Jeff's extensive clinical development experience with electroporation and intertumoral gene delivery technologies aligns perfectly with OncoSec's mission of utilizing intratumoral electroporation to achieve targeted and sustained delivery of IL-12 for significantly underserved cancer patients. He will be replacing John Rodriguez, former Vice President of Product Engineering and Manufacturing, who is retiring after five years at OncoSec," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec. "As we continue advancing our lead product candidate, TAVO™, through clinical trials, we believe Jeff's prior experience in R&D and commercialization of electroporation and gene delivery devices will be crucial in our mission to deliver this treatment directly into patients' tumors, thereby avoiding system toxicities while still having a whole-body anti-tumor effect, in the hopes of providing long-term benefits." Mr. Silverman added, "The preliminary data seen in OncoSec's clinical trials evaluating TAVO™ in combination with KEYTRUDA® for the treatment of anti-PD-1 checkpoint refractory metastatic melanoma and for metastatic triple-negative breast cancer present an encouraging path toward bringing this therapy to market. I look forward to working with Dan and the leadership team to develop and execute OncoSec's clinical trial strategy and lead manufacturing operations." Mr. Silverman earned his bachelor's degree in biology with minors in chemistry and psychology at the University of California, San Diego (UCSD). As of June 14, 2021, Mr. Silverman will be granted an initial grant of 35,000 stock options. These stock options will have an exercise price equal to the closing price of the Company's common stock on the date of grant and will be 25% vested on the date of grant, with the remaining 75% vesting quarterly over a two-year period. These stock options were granted as an inducement to Mr. Silverman entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). About TAVO™ About OncoSec Medical Incorporated KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S. TAVO™ is a trademark of OncoSec Medical Incorporated. Risk Factors and Forward-Looking Statements Company Contact Media Contact
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-industry-leading-electroporation-device-expert-jeffrey-silverman-as-vice-president-of-product-engineering-301311452.html SOURCE OncoSec Medical Incorporated |
||
Company Codes: NASDAQ-SMALL:ONCS |